Polocaine(r) -mpf (mepivacaine Hci)
Generic Name: polocaine(r) -mpf (mepivacaine hci)
Brand Names:
Polocaine(r) -mpf (mepivacaine Hci)
DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2, 6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: C 15H 22N 2O • HCl It is a white, crystalline, odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis.
Overview
DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2, 6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: C 15H 22N 2O • HCl It is a white, crystalline, odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis.
Uses
INDICATIONS & USAGE POLOCAINE (Mepivacaine HCl Injection, USP), is indicated for production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks. The routes of administration and indicated concentrations for mepivacaine are: See DOSAGE & ADMINISTRATION for additional information. Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of mepivacaine. INDICATIONS & USAGE
Dosage
DOSAGE & ADMINISTRATION The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of mepivacaine hydrochloride should be reduced for elderly and debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional doses should be used when feasible.
Side Effects
ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Reactions to mepivacaine are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection, or slow metabolic degradation. Systemic The most commonly encountered acute adverse experiences which demand immediate countermeasures are related to the central nervous system and the cardiovascular system.
Warnings
WARNINGS LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT, AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and PRECAUTIONS ). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE, AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. CONTRAINDICATIONS Mepivacaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type or to other components of solutions of mepivacaine.
Storage
HOW SUPPLIED POLOCAINE(R) -MPF (MEPIVACAINE HCI INJECTION, USP) is supplied in the following dosage forms. NDC 51662-1403-1 POLOCAINE(R) -MPF (MEPIVACAINE HCI INJECTION, USP) 1% 300mg per 30mL (10mg per mL) 30mL VIAL NDC 51662-1403-2 POLOCAINE(R) -MPF (MEPIVACAINE HCI INJECTION, USP) 1% 300mg per 30mL (10mg per mL) 30mL VIAL, 1 VIAL/POUCH NDC 51662-1403-3 POLOCAINE(R) -MPF (MEPIVACAINE HCI INJECTI...
Frequently Asked Questions
What is Polocaine(r) -mpf (mepivacaine Hci) used for?▼
INDICATIONS & USAGE POLOCAINE (Mepivacaine HCl Injection, USP), is indicated for production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks. The routes of administration and indicated concentrations for mepivacaine are: See DOSAGE & ADMINISTRATION for additional information. Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of mepivacaine. INDICATIONS & USAGE
What are the side effects of Polocaine(r) -mpf (mepivacaine Hci)?▼
ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Reactions to mepivacaine are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection, or slow metabolic degradation. Systemic The most commonly encountered acute adverse experiences which demand immediate countermeasures are related to the central nervous system and the cardiovascular system.
What are the important warnings for Polocaine(r) -mpf (mepivacaine Hci)?▼
WARNINGS LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT, AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and PRECAUTIONS ). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE, AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. CONTRAINDICATIONS Mepivacaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type or to other components of solutions of mepivacaine.
Related Medications
Cineraria Maritima, Eye (suis), Calcarea Fluorica, Causticum, Phosphorus, Silicea, Zincum Metallicum, Germanium Metallicum, Natrum Muriaticum
cineraria maritima, eye (suis), calcarea fluorica, causticum, phosphorus, silicea, zincum metallicum, germanium metallicum, natrum muriaticum
PURPOSE: Aids in maintaining eye health related to aging.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Etomidate Injection, Solution
etomidate injection, solution
General Anesthetic [EPC]
DESCRIPTION Etomidate Injection, USP is a sterile, non-pyrogenic, clear, colorless solution, free from visible particles. Each milliliter contains etomidate USP 2 mg, propylene glycol 35% v/v. The pH is 6.0 (4.0 to 7.0). It is intended for the induction of general anesthesia by intravenous injection. The drug etomidate is chemically identified as (R)-(+)-ethyl-1-(1-phenylethyl)-1H-imidazole-5-carboxylate and has the following structural formula: Structure
Diphenhydramine Hydrochloride, Pramoxine Hydrochloride
diphenhydramine hydrochloride, pramoxine hydrochloride
Purposes Topical analgesic Topical analgesic
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.